The Academy for Clinical Debates & Controversies in Medicine COHEM. Controversies in Hematology ROME ITALY SEPTEMBER 2-5, 2010 SECOND ANNOUNCEMENT

Size: px

Start display at page:

Download "The Academy for Clinical Debates & Controversies in Medicine COHEM. Controversies in Hematology ROME ITALY SEPTEMBER 2-5, 2010 SECOND ANNOUNCEMENT"

Bernice Weaver
5 years ago
Views:

ABSTRACTS A comprehensive Congress fully devoted to clinical debates and

1 The Academy for Clinical Debates & Controversies in Medicine COHEM The 1 st World Congress on Controversies in Hematology SECOND ANNOUNCEMENT AND CALL FOR ABSTRACTS A comprehensive Congress fully devoted to clinical debates and controversial issues in the field of Hematology cohem@comtecmed.com

Dear Friends and Colleagues, Over the years, the field of Hematology has undergone enormous expansion in clinical trials and basic research as well as in cutting-edge technology.

2 Dear Friends and Colleagues, Over the years, the field of Hematology has undergone enormous expansion in clinical trials and basic research as well as in cutting-edge technology. The 1 st World Congress on Controversies in Hematology (COHEM) will function as an exclusive forum for international experts to share and compare experiences, in order to outline the right treatment for patients. The concept of this Congress stems from the fact that current congresses fail to promote true clinical discussion between practicing physicians and researchers on unresolved pressing issues. Participants will have the advantage of discussing and debating these unresolved issues with leading world experts in all fields of Hematology. Allowing ample time for speaker-audience discussion, the Congress aims at reaching up-to-date and agreedupon answers to ongoing debates even when proof is lacking, through evidence-based medicine and expert opinion. We invite you to take part in the 1 st COHEM Congress which is intended as the inaugural event of many future editions. We look forward to an exciting event in the beautiful city of Rome. Prof. E. Rachmilewitz & Prof. G. Saglio Co-Chairpersons On behalf of the Organizing Committee 2

3 Chairpersons E. Rachmilewitz, Israel G. Saglio, Italy Organizing Committee S. Amadori, Italy R. Foà, Italy R. Hehlmann, Germany A. Nagler, Israel Scientific Committee M. Baccarani, Italy M. Björkholm, Sweden A. Falanga, Italy J. Goldman, UK H. Kantarjian, USA M.M. Samama, France J.F. San-Miguel, Spain C. Schiffer, USA S. Amadori, Italy W. Arcese, Italy M. Attal, France M. Baccarani, Italy A. Bacigalupo, Italy T. Barbui, Italy B. Barlogie, USA V. Berdoukas, Greece M. Björkholm, Sweden M. Boccadoro, Italy A. Burnett, UK C. Buske, Germany J. Bussel, USA F. Caligaris-Cappio, Italy M.D. Cappellini, Italy M. Cazzola, Italy P. Corradini, Italy B. de Pauw, The Netherlands V. Diehl, Germany P. Donnelly, The Netherlands A. Falanga, Italy R. Foà, Italy G. Gaidano, Italy N. Gattermann, Germany F. Giles, USA C. Gisselbrecht, France Faculty B. Godeau, France J. Goldman, UK A. Goldstone, UK D. Grimwade, UK F. Guilhot, France A. Hagenbeek, The Netherlands R. Hehlmann, Germany A. Hochhaus, Germany D. Hoelzer, Germany M. Hutchings, Denmark A. Kakkar, UK H. Kantarjian, USA G. Kontoghiorghes, Cyprus N. Kröger, Germany G. Leone, Italy A. Levis, Italy F. Lo-Coco, Italy B. Löwenberg, The Netherlands L. Luzzatto, Italy J. Maciejewski, USA F. Mahon, France J.P. Marie, France D. Marin, UK M. Martelli, Italy G. Marti, USA F. Menichetti, Italy A. Nagler, Israel O. Ottmann, Germany A. Palumbo, Italy M. Pfreundschuh, Germany U. Platzbecker, Germany A. Polliack, Israel C. Portlock, USA A. Prentice, UK E. Rachmilewitz, Israel K. Rai, USA A. Rambaldi, Italy J. Ribera, Spain S. Rivella, USA G. Saglio, Italy M.M. Samama, France J.F. San-Miguel, Spain V. Santini, Italy M.A. Sanz, Spain C. Schiffer, USA D. Straus, USA C. Tarella, Italy A. Tefferi, USA E. Terpos, Greece W. Vainchenker, France A.M. Vannucchi, Italy U. Vitolo, Italy 3

4 FRIDAY, SEPTEMBER 3, :30-10:00 PLENARY SESSION 1 Hall A Did we substantially improve MDS therapy in the last decade? Moderator: E. Rachmilewitz Yes: H. Kantarjian No: C. Schiffer Is there a role for SCT in Multiple Myeloma? Moderator: N. Kröger Yes: B. Barlogie No: M. Boccadoro 10:30-12:30 SESSION 2 Hall A ACUTE MYELOID LEUKEMIA (AML) I About targeted therapies in AML: Have standard treatments reached their limits? Moderator: S. Amadori Yes: A. Burnett No: B. Löwenberg Should the therapy of AML be driven by MRD quantification? Moderator: B. Löwenberg Yes: S. Amadori No: C. Schiffer 14:30-16:00 SESSION 3 Hall A ACUTE MYELOID LEUKEMIA (AML) II and ACUTE PROMYELOCYTIC LEUKEMIA (APL) Do we require chemotherapy to cure APL? Moderator: A. Burnett Yes: M.A. Sanz No: F. Lo-Coco Can novel prognostic markers predict for success and guide therapy in AML? Moderator: C. Schiffer Yes: D. Grimwade No: A. Burnett 16:30-18:00 SESSION 4 Hall A ACUTE LYMPHATIC LEUKEMIA (ALL) Is the efficacy of the pediatric-like protocols for ALL superior to the protocols for adult ALL? Moderator: R. Foà Yes: J.P. Marie No: J. Ribera Should the induction for Ph+ ALL be based on TKI alone or TKI plus chemotherapy? Moderator: J.P. Marie TKI Alone: R. Foà TKI plus chemotherapy: O. Ottmann 4

5 FRIDAY, SEPTEMBER 3, :30-12:30 SESSION 5 Hall B CHRONIC LYMPHATIC LEUKEMIA (CLL) Is eradication of MRD feasible and worthwhile in CLL? Moderator: K. Rai Yes: G. Marti No: G. Gaidano Is the wait and watch philosophy still practical in the treatment of CLL even in younger patients? Moderator: A. Polliack Yes: K. Rai No: F. Caligaris-Cappio 14:30-16:00 SESSION 6 Hall B INDOLENT NON-HODGKIN S LYMPHOMAS (NHL) Is there a role for Rituximab in maintenance treatment in non-follicular indolent lymphomas? Moderator: C. Portlock Yes: A. Hagenbeek No: C. Buske Is molecular remission the goal in first line therapy of all patients with indolent non-hodgkin lymphoma? Moderator: A. Hagenbeek Yes: P. Corradini No: C. Tarella 16:30-18:00 SESSION 7 Hall B MULTIPLE MYELOMA (MM) Multiple Myeloma in patients <70 years: cure vs. disease control Moderator: M. Boccadoro Cure: J.F. San-Miguel Control: A. Palumbo Should Therapy for newly diagnosed MM be risk adapted? Moderator: A. Palumbo Yes: M. Attal No: E. Terpos 5

6 SATURDAY, SEPTEMBER 4, :30-10:00 SESSION 8 Hall A STEM CELL TRANSPLANATION (SCT) I The role of Allogeneic SCT (AlloSCT) in Hematological Malignancies How should we treat a 60 year old patient with Myelodysplastic syndrome? Moderator: M. Martelli AlloSCT: N. Kröger Conventional Therapy: U. Platzbecker Should all adult ALL patients have a stem cell transplantation in first remission or only high risk patients? Moderator: W. Arcese All: A. Goldstone Only high risk: D. Hoelzer 10:30-12:30 SESSION 9 Hall A STEM CELL TRANSPLANATION (SCT) II Alternative Donor and Reduced Intensity Conditioning (RIC) AlloSCT Should CBT, Haploidentical transplant or MUD transplant be considered upfront if no sibling donor is available? Moderator: A. Rambaldi CBT: W. Arcese Haplo: M. Martelli MUD: A. Bacigalupo Should we use AlloSCT in Acute Myeloid Leukemia RIC or Myeloablative preparative protocols? Moderator: A. Bacigalupo RIC: A. Nagler Myeloablative: A. Rambaldi 14:30-16:00 SESSION 10 Hall A MDS Do hypomethylating agents improve survival in patients with high risk myelodysplastic syndromes? Moderator: G. Leone Yes: V. Santini No: M. Cazzola Is there a rationale for iron chelation therapy in MDS? Moderator: E. Rachmilewitz Yes: N. Gattermann No: A. Tefferi 6

SATURDAY, SEPTEMBER 4, 2010 16:30-18:00 SESSION 11 Hall A HODGKIN AND NON-HODGKIN LYMPHOMAS Has PET/CT an established role in the management of HD and NHLs? Moderator: M.

7 SATURDAY, SEPTEMBER 4, :30-18:00 SESSION 11 Hall A HODGKIN AND NON-HODGKIN LYMPHOMAS Has PET/CT an established role in the management of HD and NHLs? Moderator: M. Björkholm Yes: M. Hutchings No: U. Vitolo Does molecular outcome prediction in DLBCL add clinical value? Moderator: M. Björkholm Yes: C. Gisselbrecht No: M. Pfreundschuh 7

8 SATURDAY, SEPTEMBER 4, :30-10:00 SESSION 12 Hall B CHRONIC MYELOID LEUKEMIA (CML) I Will second generation TKIs substitute imatinib as first line treatment of CML? Moderator: R. Hehlmann Yes: M. Baccarani No: H. Kantarjian Can we eventually stop TKI in all CML patients? Moderator: M. Baccarani Yes: F. Mahon No: J. Goldman 10:30-12:30 SESSION 13 Hall B CHRONIC MYELOID LEUKEMIA (CML) II Is mutation analysis of BCR ABL of any value in clinical management of CML patients? Moderator: J. Goldman Yes: A. Hochhaus No: D. Marin Should first line imatinib treatment be optimized by combination with IFN or by higher imatinib dose? Moderator: A. Hochhaus Combination with IFN: F. Guilhot Higher initial imatinib dose: R. Hehlmann On the road to cure CML, does it matter to hit different pathways? Yes: F. Giles No: 14:30-16:00 SESSION 14 Hall B COAGULATION Are there indications for thrombophylaxis in cancer patients during and after chemotherapy? Moderator: M.M. Samama Yes: A. Falanga No: A. Kakkar Is there still a role for splenectomy in ITP? Moderator: A. Falanga Yes: B. Godeau No: J. Bussel 8

SATURDAY, SEPTEMBER 4, 2010 16:30-18:30 SESSION 15 Hall B HEMOGLOBINOPATHIES & PNH Pros and cons of gene therapy in beta-thalassemia Moderator: L. Luzzatto Lecture: S.

9 SATURDAY, SEPTEMBER 4, :30-18:30 SESSION 15 Hall B HEMOGLOBINOPATHIES & PNH Pros and cons of gene therapy in beta-thalassemia Moderator: L. Luzzatto Lecture: S. Rivella The controversies in the use of chelating drugs for the treatment of iron overload affect the morbidity and mortality of thalassaemia and other transfused patients worldwide Moderator: E. Rachmilewitz Lecture: G. Kontoghiorghes How far one should go with iron chelation in thalassemia? Is iron deficiency indicated? Moderator: E. Rachmilewitz Yes: V. Berdoukas No: M.D. Cappellini Do the benefits of complement blockade extend to all patients with PNH clone? Yes: J. Maciejewski No: L. Luzzatto 9

10 SUNDAY, SEPTEMBER 5, :30-10:00 SESSION 16 Hall A MPNS (MYELO PROLIFERATIVE NEOPLAMS) Are JAK2 positive PV, ET and IM different diseases? Moderator: A. Tefferi Yes: W. Vainchenker No: A.M. Vannucchi Do JAK2 inhibitors represent a major advance in the treatment of myeloproliferative neoplasms? Moderator: W. Vainchenker Yes: A. Tefferi No: T. Barbui 08:30-10:00 SESSION 17 Hall B INFECTIONS Is there a role for empirical or pre-emptive antifungal treatment in patients with hematological malignancies? Moderator: F. Menichetti Yes: B. de Pauw No: A. Prentice Is monitoring of azole concentrations of clinical value in pts with hematological malignancies? Moderator: B. de Pauw Yes: F. Menichetti No: P. Donnelly 10:30-12:30 PLENARY SESSION 18 Hall A Is there a role of biologic prognostic markers in the treatment of CLL? Moderator: E. Rachmilewitz For: R. Foà Against: K. Rai Are there sufficient indications for switching to new anticoagulant agents? Moderator: G. Saglio For: M.M. Samama Against: A. Falanga Which is the best chemotherapy regimen in Hodgkin s Lymphoma? Moderator: D. Straus ABVD: A. Levis BEACOPP: V. Diehl Is chemotherapy alone sufficient for the treatment of Hodgkin s Lymphoma? Lecture: D. Straus Deadline for abstract submission: JUNE 21, 2010 We are pleased to announce a competition for the BEST ABSTRACTS. Six prizes of Є500 each will be awarded to the most outstanding abstracts! 10

11 GENERAL INFORMATION DATES September 2-5, 2010 VENUE Sheraton Roma Hotel & Conference Center Viale Del Pattinaggio, 100. Rome, Italy Tel: Fax: REGISTRATION FEES Early Registration Late Registration From Aug 26, 2010 Until from June 22 until and On Site June 21, 2010 Aug 25, 2010 Participants - - Physicians and Scientists Є 540 Є 590 Є 650 Residents, Nurses, Students Є 385 Є 430 Є 470 Accompanying Persons Є 140 Registration fees include: Participation in scientific sessions, Congress bag, program and abstract book, all printed material of the Congress and invitation to the Welcome Reception. ACCOMMODATION ComtecMed is the official travel agent for the 1 st World Congress on Controversies in Hematology (COHEM), and will be offering special reduced rates for accommodation. LIABILITY AND INSURANCE The Congress Secretariat and Organizers cannot accept liability for personal accidents, nor loss of or damage to private property of participants, either during or directly arising from the 1 st World Congress on Controversies in Hematology (COHEM). Participants should make their own arrangements with respect to health and travel insurance. 11

12 COHEM The 1 st World Congress on Controversies in Hematology Rome Italy September 2-5, 2010 cohem@comtecmed.com cohem@comtecmed.com Headquarters and Administration: 53 Rothschild Boulevard, PO Box 68, Tel Aviv 61000, Israel Tel: Fax: info@comtecmed.com Comtec Spain: Bailén, 95-97, pral. 1. a Barcelona, Spain Tel: Fax: spain@comtecmed.com Comtec China: 175 Xiang Yang Road South, Shanghai China Tel: Fax: china@comtecmed.com

Overview of CML related sessions at 21 th EHA Meeting in Copenhagen Preliminary Program

Overview of CML related sessions at 21 th EHA Meeting in Copenhagen Preliminary Program Time slots Sessions Location June 9 th (Thursday) 8.00 10.00 Satellite Symposium: Improving outcomes: individualising